ThromboGenics Ltd. Announces the Exercise of 172,629 Warrants

Leuven, Belgium – May 28, 2008 – ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular diseases, eye diseases and cancer, announces today the quotation on Euronext Brussels of 172,629 new shares, created as a consequence of the exercise of 172,629 warrants on April 7, 2008. This transaction strengthens ThromboGenics’ cash position with an amount of 893,277 EUR. Following the issue of the new shares, the Company's number of outstanding shares increases from 25,502,160 to 25,674,789.

For further information please contact:

ThromboGenics Chris Buyse, CFO Tel: +32 (0) 16 34 61 94 chris.buyse@thrombogenics.com Citigate Dewe Rogerson David Dible/ Sylvie Berrebi/ Amber Bielecka Tel: +44 (0) 207 638 95 71 sylvie.berrebi@citigatedr.co.uk

About ThromboGenics ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in 2008, and TB-403 (Anti-PlGF), which is scheduled to enter a Phase Ib clinical trial in mid-2008 for the treatment of cancer. ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at www.thrombogenics.com.